{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:09:33Z","timestamp":1770516573545,"version":"3.49.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00228-021-03088-y","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T22:02:56Z","timestamp":1611957776000},"page":"1095-1111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes"],"prefix":"10.1007","volume":"77","author":[{"given":"Tingyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yitian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-7204","authenticated-orcid":false,"given":"Guosheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"issue":"12","key":"3088_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/jnci\/djz090","volume":"111","author":"CH Lin","year":"2019","unstructured":"Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SM, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS, The Asian Breast Cancer Cooperative Group (2019) Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst 111(12):1298\u20131306","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3088_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10549-010-1173-8","volume":"127","author":"ML Telli","year":"2011","unstructured":"Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D et al (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 127(2):471\u2013478","journal-title":"Breast Cancer Res Treat"},{"issue":"4\u20135","key":"3088_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jsbmb.2009.12.017","volume":"118","author":"CS Huang","year":"2010","unstructured":"Huang CS, Lin CH, Lu YS, Shen CY (2010) Unique features of breast cancer in Asian women--breast cancer in Taiwan as an example. J Steroid Biochem Mol Biol 118(4\u20135):300\u2013303","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"3088_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12282-015-0599-6","volume":"22","author":"J Kurebayashi","year":"2015","unstructured":"Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T et al (2015) Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast cancer (Tokyo, Japan) 22(3):235\u2013244","journal-title":"Breast cancer (Tokyo, Japan)"},{"key":"3088_CR5","doi-asserted-by":"crossref","unstructured":"Mokbel K, Mokbel K (2017) Does CYP2D6 genotyping have a role in guiding tamoxifen therapy? Biochem Mol Biol J 03(03)","DOI":"10.21767\/2471-8084.100041"},{"issue":"1","key":"3088_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10549-011-1777-7","volume":"131","author":"K Kiyotani","year":"2012","unstructured":"Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M, Sasa M, Nakamura Y, Zembutsu H (2012) Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat 131(1):137\u2013145","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3088_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","volume":"132","author":"W Lorizio","year":"2012","unstructured":"Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 132(3):1107\u20131118","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"3088_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 102(4):688\u2013700","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3088_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS (2017) Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine: Official Journal of the American College of Medical Genetics 19(1):69\u201376","journal-title":"Genetics in Medicine: Official Journal of the American College of Medical Genetics"},{"issue":"3","key":"3088_CR10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1124\/jpet.104.065607","volume":"310","author":"Z Desta","year":"2004","unstructured":"Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310(3):1062\u20131075","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3088_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30\u201339","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"3088_CR12","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/jnci\/djg108","volume":"95","author":"V Stearns","year":"2003","unstructured":"Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95(23):1758\u20131764","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3088_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AHB, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89(5):718\u2013725","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"3088_CR14","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1158\/1055-9965.EPI-11-0419","volume":"20","author":"TP Ahern","year":"2011","unstructured":"Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, S\u00f8iland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, S\u00f8rensen HT, Lash TL, Hamilton-Dutoit S (2011) Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiology, Biomarkers & Prevention: a Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20(9):1937\u20131943","journal-title":"Cancer Epidemiology, Biomarkers & Prevention: a Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"1","key":"3088_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/annonc\/mdm434","volume":"19","author":"J Gjerde","year":"2008","unstructured":"Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 19(1):56\u201361","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology."},{"issue":"47","key":"3088_CR16","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","volume":"22","author":"R Clarke","year":"2003","unstructured":"Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 22(47):7316\u20137339","journal-title":"Oncogene."},{"issue":"2","key":"3088_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","volume":"85","author":"MD Johnson","year":"2004","unstructured":"Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85(2):151\u2013159","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"3088_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00280-004-0926-7","volume":"55","author":"YC Lim","year":"2005","unstructured":"Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55(5):471\u2013478","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6\u20137","key":"3088_CR19","first-page":"741","volume":"64","author":"AE Wakeling","year":"1980","unstructured":"Wakeling AE, Slater SR (1980) Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treatment Reports 64(6\u20137):741\u2013744","journal-title":"Cancer Treatment Reports"},{"issue":"8","key":"3088_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrc2683","volume":"9","author":"JM Hoskins","year":"2009","unstructured":"Hoskins JM, Carey LA, McLeod HL (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9(8):576\u2013586","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3088_CR21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/clpt.2011.27","volume":"89","author":"TE M\u00fcrdter","year":"2011","unstructured":"M\u00fcrdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89(5):708\u2013717","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"3088_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/FPC.0b013e3283629ce9","volume":"23","author":"A Fohner","year":"2013","unstructured":"Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T et al (2013) Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics 23(8):403\u2013414","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"3088_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygeno.2008.05.004","volume":"92","author":"S Qin","year":"2008","unstructured":"Qin S, Shen L, Zhang A, Xie J, Shen W, Chen L, Tang J, Xiong Y, Yang L, Shi Y, Feng G, He L, Xing Q (2008) Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics. 92(3):152\u2013158","journal-title":"Genomics."},{"issue":"7","key":"3088_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/clinchem\/48.7.983","volume":"48","author":"L Ji","year":"2002","unstructured":"Ji L, Pan S, Marti-Jaun J, H\u00e4nseler E, Rentsch K, Hersberger M (2002) Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 48(7):983\u2013988","journal-title":"Clin Chem"},{"issue":"1","key":"3088_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169233","volume":"12","author":"LL Goh","year":"2017","unstructured":"Goh LL, Lim CW, Sim WC, Toh LX, Leong KP (2017) Analysis of genetic variation in CYP450 genes for clinical implementation. PLoS One 12(1):e0169233","journal-title":"PLoS One"},{"issue":"6","key":"3088_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/jhg.2011.30","volume":"56","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Yu X, Shu C, Cai Y, Gong W, Wang X, Wang DM, Hu S (2011) Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet 56(6):415\u2013422","journal-title":"J Hum Genet"},{"issue":"8","key":"3088_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/0091270009355161","volume":"50","author":"M Man","year":"2010","unstructured":"Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, Noh GJ, Njau R, Close S, Wise S, Hockett R (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major east Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 50(8):929\u2013940","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3088_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/clinchem\/46.1.18","volume":"46","author":"M Garcia-Barcel\u00f3","year":"2000","unstructured":"Garcia-Barcel\u00f3 M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL et al (2000) Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 46(1):18\u201323","journal-title":"Clin Chem"},{"issue":"6","key":"3088_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/tpj.2009.31","volume":"9","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu SN, Wang DM (2009) Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J. 9(6):380\u2013394","journal-title":"Pharmacogenomics J."},{"issue":"10","key":"3088_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10038-006-0034-0","volume":"51","author":"YH Liou","year":"2006","unstructured":"Liou YH, Lin CT, Wu YJ, Wu LS (2006) The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J Hum Genet 51(10):857\u2013863","journal-title":"J Hum Genet"},{"issue":"9","key":"3088_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.884","volume":"7","author":"W Chen","year":"2019","unstructured":"Chen W, Ding H, Cheng Y, Li Q, Dai R, Yang X, Zhang C (2019) Genetic polymorphisms analysis of pharmacogenomic VIP variants in Bai ethnic group from China. Molecular Genetics & Genomic Medicine 7(9):e884","journal-title":"Molecular Genetics & Genomic Medicine"},{"issue":"4","key":"3088_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1046\/j.1365-2125.2003.01782.x","volume":"55","author":"A Ishiguro","year":"2003","unstructured":"Ishiguro A, Kubota T, Sasaki H, Yamada Y, Iga T (2003) Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population. Br J Clin Pharmacol 55(4):414\u2013415","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3088_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/00008571-200008000-00010","volume":"10","author":"Y Nishida","year":"2000","unstructured":"Nishida Y, Fukuda T, Yamamoto I, Azuma J (2000) CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 10(6):567\u2013570","journal-title":"Pharmacogenetics."},{"issue":"8","key":"3088_CR34","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1373\/clinchem.2009.123620","volume":"55","author":"N Hosono","year":"2009","unstructured":"Hosono N, Kato M, Kiyotani K, Mushiroda T, Takata S, Sato H, Amitani H, Tsuchiya Y, Yamazaki K, Tsunoda T, Zembutsu H, Nakamura Y, Kubo M (2009) CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin Chem 55(8):1546\u20131554","journal-title":"Clin Chem"},{"issue":"5","key":"3088_CR35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S0009-9236(99)70077-9","volume":"65","author":"T Tateishi","year":"1999","unstructured":"Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65(5):570\u2013575","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3088_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7150\/ijms.10263","volume":"12","author":"T Ota","year":"2015","unstructured":"Ota T, Kamada Y, Hayashida M, Iwao-Koizumi K, Murata S, Kinoshita K (2015) Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population. Int J Med Sci 12(1):78\u201382","journal-title":"Int J Med Sci"},{"issue":"7","key":"3088_CR37","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1124\/dmd.108.022368","volume":"37","author":"SJ Lee","year":"2009","unstructured":"Lee SJ, Lee SS, Jung HJ, Kim HS, Park SJ, Yeo CW, Shin JG (2009) Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab Dispos 37(7):1464\u20131470","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3088_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/01.ftd.0000211823.80854.db","volume":"28","author":"SY Lee","year":"2006","unstructured":"Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW (2006) Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 28(3):382\u2013387","journal-title":"Ther Drug Monit"},{"issue":"3","key":"3088_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1365-2710.2001.00347.x","volume":"26","author":"LK Teh","year":"2001","unstructured":"Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR (2001) Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 26(3):205\u2013211","journal-title":"J Clin Pharm Ther"},{"issue":"22","key":"3088_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015891","volume":"98","author":"HH Nguyen","year":"2019","unstructured":"Nguyen HH, Ma TTH, Vu NP, Bach QTN, Vu TH, Nguyen TD, Nong HV (2019) Single nucleotide and structural variants of CYP2D6 gene in Kinh Vietnamese population. Medicine (Baltimore) 98(22):e15891","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"3088_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00228-008-0573-8","volume":"65","author":"MI Veiga","year":"2009","unstructured":"Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, Hai TN, Petzold MG, Bj\u00f6rkman A, Ashton M, Gil JP (2009) Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 65(4):355\u2013363","journal-title":"Eur J Clin Pharmacol"},{"key":"3088_CR42","doi-asserted-by":"crossref","unstructured":"Le VS, Tran KT, Bui HTP, Le HTT, Nguyen CD, Do DH et al (2019) A Vietnamese human genetic variation database. 40(10):1664\u20131675","DOI":"10.1002\/humu.23835"},{"issue":"13","key":"3088_CR43","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.clinbiochem.2011.06.985","volume":"44","author":"P Suwannasri","year":"2011","unstructured":"Suwannasri P, Thongnoppakhun W, Pramyothin P, Assawamakin A, Limwongse C (2011) Combination of multiplex PCR and DHPLC-based strategy for CYP2D6 genotyping scheme in Thais. Clin Biochem 44(13):1144\u20131152","journal-title":"Clin Biochem"},{"issue":"8","key":"3088_CR44","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1248\/bpb.29.1655","volume":"29","author":"AT Naveen","year":"2006","unstructured":"Naveen AT, Adithan C, Soya SS, Gerard N, Krishnamoorthy R (2006) CYP2D6 genetic polymorphism in south Indian populations. Biol Pharm Bull 29(8):1655\u20131658","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"3088_CR45","doi-asserted-by":"publisher","first-page":"7323","DOI":"10.1038\/s41598-019-43736-z","volume":"9","author":"NA Afsar","year":"2019","unstructured":"Afsar NA, Bruckmueller H, Werk AN, Nisar MK, Ahmad HR, Cascorbi I (2019) Implications of genetic variation of common drug metabolizing enzymes and ABC transporters among the Pakistani population. Sci Rep 9(1):7323","journal-title":"Sci Rep"},{"key":"3088_CR46","doi-asserted-by":"publisher","first-page":"144408","DOI":"10.1016\/j.gene.2020.144408","volume":"737","author":"LN Al-Eitan","year":"2020","unstructured":"Al-Eitan LN (2020) Pharmacogenomic landscape of VIP genetic variants in Jordanian Arabs and comparison with worldwide populations. Gene. 737:144408","journal-title":"Gene."},{"issue":"2","key":"3088_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/cp.1999.v66.100072001","volume":"66","author":"AS Aynacioglu","year":"1999","unstructured":"Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schr\u00f6der T et al (1999) Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 66(2):185\u2013192","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3088_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00008571-199706000-00003","volume":"7","author":"RA McLellan","year":"1997","unstructured":"McLellan RA, Oscarson M, Seideg\u00e5rd J, Evans DA, Ingelman-Sundberg M (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 7(3):187\u2013191","journal-title":"Pharmacogenetics."},{"issue":"1","key":"3088_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3088_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/tpj.2013.2","volume":"14","author":"DP Dai","year":"2014","unstructured":"Dai DP, Xu RA, Hu LM, Wang SH, Geng PW, Yang JF, Yang LP, Qian JC, Wang ZS, Zhu GH, Zhang XH, Ge RS, Hu GX, Cai JP (2014) CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J. 14(1):85\u201392","journal-title":"Pharmacogenomics J."},{"issue":"6","key":"3088_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2217\/14622416.9.6.691","volume":"9","author":"L Chen","year":"2008","unstructured":"Chen L, Qin S, Xie J, Tang J, Yang L, Shen W, Zhao X, du J, He G, Feng G, He L, Xing Q (2008) Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics. 9(6):691\u2013702","journal-title":"Pharmacogenomics."},{"issue":"12","key":"3088_CR52","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1093\/clinchem\/45.12.2273","volume":"45","author":"M Garcia-Barcel\u00f3","year":"1999","unstructured":"Garcia-Barcel\u00f3 M, Chow LY, Kum Chiu HF, Wing YK, Shing Lee DT, Lam KL et al (1999) Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4. Clin Chem 45(12):2273\u20132274","journal-title":"Clin Chem"},{"issue":"3","key":"3088_CR53","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2125.2004.02144.x","volume":"58","author":"YS Pang","year":"2004","unstructured":"Pang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC (2004) Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol 58(3):332\u2013335","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3088_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","volume":"7","author":"JA Goldstein","year":"1997","unstructured":"Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM et al (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 7(1):59\u201364","journal-title":"Pharmacogenetics."},{"issue":"1\u20132","key":"3088_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cccn.2004.11.005","volume":"353","author":"YF Hu","year":"2005","unstructured":"Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C, Duan LF, Zhou HH (2005) CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353(1\u20132):187\u2013192","journal-title":"Clin Chim Acta"},{"issue":"6","key":"3088_CR56","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2217\/14622416.7.6.831","volume":"7","author":"J Du","year":"2006","unstructured":"Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y et al (2006) Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics. 7(6):831\u2013841","journal-title":"Pharmacogenomics."},{"issue":"3","key":"3088_CR57","first-page":"268","volume":"29","author":"KP Hsieh","year":"2001","unstructured":"Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP et al (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29(3):268\u2013273","journal-title":"Drug Metab Dispos"},{"issue":"9\u201310","key":"3088_CR58","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cca.2010.12.038","volume":"412","author":"R Yuan","year":"2011","unstructured":"Yuan R, Zhang X, Deng Q, Wu Y, Xiang G (2011) Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clin Chim Acta 412(9\u201310):755\u2013760","journal-title":"Clin Chim Acta"},{"issue":"2","key":"3088_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2710.2011.01268.x","volume":"37","author":"ZL Dong","year":"2012","unstructured":"Dong ZL, Li H, Chen QX, Hu Y, Wu SJ, Tang LY, Gong WY, Xie GH, Fang XM (2012) Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population. J Clin Pharm Ther 37(2):153\u2013156","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"3088_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00228-003-0594-2","volume":"59","author":"C Balram","year":"2003","unstructured":"Balram C, Zhou Q, Cheung YB, Lee EJ (2003) CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 59(2):123\u2013126","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3088_CR61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/gepi.21711","volume":"37","author":"X Dai","year":"2013","unstructured":"Dai X, Wu C, He Y, Gui L, Zhou L, Guo H, Yuan J, Yang B, Li J, Deng Q, Huang S, Guan L, Hu D, Zhu J, Min X, Lang M, Li D, Yang H, Hu FB, Lin D, Wu T, He M (2013) A genome-wide association study for serum bilirubin levels and gene-environment interaction in a Chinese population. Genet Epidemiol 37(3):293\u2013300","journal-title":"Genet Epidemiol"},{"issue":"12","key":"3088_CR62","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40261-017-0572-6","volume":"37","author":"Q Sun","year":"2017","unstructured":"Sun Q, Liu HP, Zheng RJ, Wang P, Liu ZB, Sha W, Xiao HP (2017) Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: a Chinese population-based prospective case-control study. Clinical Drug Investigation 37(12):1125\u20131136","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"3088_CR63","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3349\/ymj.2014.55.1.232","volume":"55","author":"JY Kim","year":"2014","unstructured":"Kim JY, Cheong HS, Park BL, Kim LH, Namgoong S, Kim JO, Kim HD, Kim YH, Chung MW, Han SY, Shin HD (2014) Comprehensive variant screening of the UGT gene family. Yonsei Med J 55(1):232\u2013239","journal-title":"Yonsei Med J"},{"key":"3088_CR64","doi-asserted-by":"crossref","unstructured":"Huangfu H, Pan H, Wang B, Wen S, Han R, Li L (2016) Association between UGT1A1 Polymorphism and Risk of Laryngeal Squamous Cell Carcinoma. International Journal of Environmental Research and Public Health 13(1)","DOI":"10.3390\/ijerph13010112"},{"issue":"1","key":"3088_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2710.2007.00791.x","volume":"32","author":"D Li","year":"2007","unstructured":"Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY (2007) Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther 32(1):89\u201395","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"3088_CR66","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00008571-200208000-00004","volume":"12","author":"K Tang","year":"2002","unstructured":"Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS et al (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 12(6):437\u2013450","journal-title":"Pharmacogenetics."},{"issue":"3","key":"3088_CR67","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00008571-200104000-00005","volume":"11","author":"MM Ameyaw","year":"2001","unstructured":"Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang\u00e1 J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 11(3):217\u2013221","journal-title":"Pharmacogenetics."},{"issue":"2","key":"3088_CR68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00008571-200302000-00005","volume":"13","author":"B Chowbay","year":"2003","unstructured":"Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 13(2):89\u201395","journal-title":"Pharmacogenetics."},{"issue":"4","key":"3088_CR69","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1365-2125.2005.02448.x","volume":"60","author":"JW Bae","year":"2005","unstructured":"Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY (2005) Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60(4):418\u2013422","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3088_CR70","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2133\/dmpk.20.300","volume":"20","author":"H Fukushima-Uesaka","year":"2005","unstructured":"Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Tohkin M, Sawada JI (2005) Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet. 20(4):300\u2013307","journal-title":"Drug Metab Pharmacokinet."},{"issue":"3","key":"3088_CR71","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2125.2007.03057.x","volume":"65","author":"K Sugimoto","year":"2008","unstructured":"Sugimoto K, Uno T, Yamazaki H, Tateishi T (2008) Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 65(3):437\u2013439","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3088_CR72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/humu.9210","volume":"23","author":"H Fukushima-Uesaka","year":"2004","unstructured":"Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto YI, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada JI (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23(1):100","journal-title":"Hum Mutat"},{"issue":"11","key":"3088_CR73","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1248\/bpb.b13-00509","volume":"36","author":"M Uesugi","year":"2013","unstructured":"Uesugi M, Hosokawa M, Shinke H, Hashimoto E, Takahashi T, Kawai T, Matsubara K, Ogawa K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S (2013) Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol Pharm Bull 36(11):1814\u20131821","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"3088_CR74","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/bcp.13561","volume":"84","author":"S Ueshima","year":"2018","unstructured":"Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H, Ohno S, Horie M, Terada T, Katsura T (2018) Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol 84(6):1301\u20131312","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3088_CR75","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00008571-200206000-00009","volume":"12","author":"S Fukuen","year":"2002","unstructured":"Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics. 12(4):331\u2013334","journal-title":"Pharmacogenetics."},{"issue":"6","key":"3088_CR76","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/jhg.2009.31","volume":"54","author":"A Saito","year":"2009","unstructured":"Saito A, Kawamoto M, Kamatani N (2009) Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects. J Hum Genet 54(6):317\u2013323","journal-title":"J Hum Genet"},{"issue":"10","key":"3088_CR77","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1023\/A:1012244520615","volume":"18","author":"T Sakaeda","year":"2001","unstructured":"Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18(10):1400\u20131404","journal-title":"Pharm Res"},{"issue":"2","key":"3088_CR78","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2133\/dmpk.21.126","volume":"21","author":"C Komoto","year":"2006","unstructured":"Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K (2006) MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 21(2):126\u2013132","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"3088_CR79","first-page":"1137","volume":"297","author":"M Tanabe","year":"2001","unstructured":"Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297(3):1137\u20131143","journal-title":"J Pharmacol Exp Ther"},{"issue":"9279","key":"3088_CR80","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(01)05579-9","volume":"358","author":"E Schaeffeler","year":"2001","unstructured":"Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM et al (2001) Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet (London, England) 358(9279):383\u2013384","journal-title":"Lancet (London, England)"},{"issue":"2","key":"3088_CR81","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1124\/jpet.302.2.804","volume":"302","author":"T Nozawa","year":"2002","unstructured":"Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302(2):804\u2013813","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"3088_CR82","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2710.2009.01069.x","volume":"35","author":"KA Kim","year":"2010","unstructured":"Kim KA, Song WK, Kim KR, Park JY (2010) Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J Clin Pharm Ther 35(6):697\u2013703","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"3088_CR83","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/FTD.0b013e31811f383c","volume":"29","author":"SS Lee","year":"2007","unstructured":"Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS et al (2007) Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit 29(4):455\u2013459","journal-title":"Ther Drug Monit"},{"issue":"3","key":"3088_CR84","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1046\/j.1365-2125.2001.00340.x","volume":"51","author":"YR Yoon","year":"2001","unstructured":"Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG (2001) Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51(3):277\u2013280","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"3088_CR85","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/aps.2011.100","volume":"32","author":"JW Bae","year":"2011","unstructured":"Bae JW, Choi CI, Kim MJ, Oh DH, Keum SK, Park JI, Kim BH, Bang HK, Oh SG, Kang BS, Park HJ, Kim HD, Ha JH, Shin HJ, Kim YH, Na HS, Chung MW, Jang CG, Lee SY (2011) Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 32(10):1303\u20131308","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"3088_CR86","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/FPC.0b013e328358dd70","volume":"22","author":"IW Kim","year":"2012","unstructured":"Kim IW, Kim KI, Chang HJ, Yeon B, Bang SJ, Park T, Kwon JS, Kim S, Oh JM (2012) Ethnic variability in the allelic distribution of pharmacogenes between Korean and other populations. Pharmacogenet Genomics 22(12):829\u2013836","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"3088_CR87","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4103\/1008-682X.133320","volume":"17","author":"JH Han","year":"2015","unstructured":"Han JH, Lee YS, Kim HJ, Lee SY, Myung SC (2015) Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population. Asian J Androl 17(2):285\u2013291","journal-title":"Asian J Androl"},{"issue":"6","key":"3088_CR88","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/1755-5922.12147","volume":"33","author":"SH An","year":"2015","unstructured":"An SH, Chang BC, Lee KE, Gwak HS (2015) Influence of UDP-glucuronosyltransferase polymorphisms on stable warfarin doses in patients with mechanical cardiac valves. Cardiovasc Ther 33(6):324\u2013328","journal-title":"Cardiovasc Ther"},{"issue":"18","key":"3088_CR89","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1093\/hmg\/ddq281","volume":"19","author":"TW Kang","year":"2010","unstructured":"Kang TW, Kim HJ, Ju H, Kim JH, Jeon YJ, Lee HC, Kim KK, Kim JW, Lee S, Kim JY, Kim SY, Kim YS (2010) Genome-wide association of serum bilirubin levels in Korean population. Hum Mol Genet 19(18):3672\u20133678","journal-title":"Hum Mol Genet"},{"issue":"4","key":"3088_CR90","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/01.ftd.0000164293.75854.11","volume":"27","author":"SS Lee","year":"2005","unstructured":"Lee SS, Kim SY, Kim WY, Thi-Le H, Yoon YR, Yea SS et al (2005) MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther Drug Monit 27(4):531\u2013535","journal-title":"Ther Drug Monit"},{"issue":"1\u20132","key":"3088_CR91","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cca.2007.05.004","volume":"383","author":"AB Ruzilawati","year":"2007","unstructured":"Ruzilawati AB, Suhaimi AW, Gan SH (2007) Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clin Chim Acta 383(1\u20132):158\u2013162","journal-title":"Clin Chim Acta"},{"issue":"1","key":"3088_CR92","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1472-8206.2004.00307.x","volume":"19","author":"R Jose","year":"2005","unstructured":"Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, Satyanarayanamoorthy K, Peter A, Rajagopal K (2005) CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundamental & Clinical Pharmacology 19(1):101\u2013105","journal-title":"Fundamental & Clinical Pharmacology"},{"issue":"3","key":"3088_CR93","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.etap.2014.03.013","volume":"37","author":"S Gulati","year":"2014","unstructured":"Gulati S, Yadav A, Kumar N, Kanupriya, Kumar G, Aggarwal N et al (2014) Frequency distribution of high risk alleles of CYP2C19, CYP2E1, CYP3A4 genes in Haryana population. Environ Toxicol Pharmacol 37(3):1186\u20131193","journal-title":"Environ Toxicol Pharmacol"},{"issue":"10","key":"3088_CR94","doi-asserted-by":"publisher","first-page":"9423","DOI":"10.1007\/s11033-012-1807-5","volume":"39","author":"AM Yousef","year":"2012","unstructured":"Yousef AM, Bulatova NR, Newman W, Hakooz N, Ismail S, Qusa H, Zahran F, Anwar Ababneh N, Hasan F, Zaloom I, Khayat G, al-Zmili R, Naffa R, al-Diab O (2012) Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep 39(10):9423\u20139433","journal-title":"Mol Biol Rep"},{"issue":"1","key":"3088_CR95","doi-asserted-by":"publisher","first-page":"261","DOI":"10.7314\/APJCP.2016.17.1.261","volume":"17","author":"AM Abuhaliema","year":"2016","unstructured":"Abuhaliema AM, Yousef AM, Elmadany NN, Bulatova NR, Awwad NM, Yousef MA et al (2016) Influence of genotype and haplotype of MDR1 (C3435T, G2677A\/T, C1236T) on the incidence of breast cancer--a case-control study in Jordan. Asian Pac J Cancer Prev 17(1):261\u2013266","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"3088_CR96","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2125.1999.00012.x","volume":"48","author":"AS Aynacioglu","year":"1999","unstructured":"Aynacioglu AS, Brockm\u00f6ller J, Bauer S, Sachse C, G\u00fczelbey P, Ongen Z et al (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48(3):409\u2013415","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3088_CR97","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/sj.tpj.6500025","volume":"1","author":"R Kerb","year":"2001","unstructured":"Kerb R, Aynacioglu AS, Brockm\u00f6ller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, \u00d6ngen HZ, G\u00fczelbey P, Roots I, Brinkmann U (2001) The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1(3):204\u2013210","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"3088_CR98","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/dna.2009.0953","volume":"29","author":"G G\u00fcm\u00fc\u015f-Akay","year":"2010","unstructured":"G\u00fcm\u00fc\u015f-Akay G, R\u00fcstemo\u011flu A, Karada\u011f A, Sunguro\u011flu A (2010) Haplotype-based analysis of MDR1\/ABCB1 gene polymorphisms in a Turkish population. DNA Cell Biol 29(2):83\u201390","journal-title":"DNA Cell Biol"},{"issue":"1\u20132","key":"3088_CR99","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1440-1681.2007.04538.x","volume":"34","author":"N Zand","year":"2007","unstructured":"Zand N, Tajik N, Moghaddam AS, Milanian I (2007) Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol 34(1\u20132):102\u2013105","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"9","key":"3088_CR100","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00384-007-0270-6","volume":"22","author":"A Farnood","year":"2007","unstructured":"Farnood A, Naderi N, Moghaddam SJ, Noorinayer B, Firouzi F, Aghazadeh R et al (2007) The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. Int J Color Dis 22(9):999\u20131003","journal-title":"Int J Color Dis"},{"issue":"1","key":"3088_CR101","first-page":"57","volume":"19","author":"M Saidijam","year":"2015","unstructured":"Saidijam M, Mahjub H, Shabab N, Yadegarazari R (2015) Simultaneous analysis of multidrug resistance 1(MDR1) C3435T, G2677T\/a, and C1236T genotypes in Hamadan City population, west of Iran. Iran Biomed J 19(1):57\u201362","journal-title":"Iran Biomed J"},{"issue":"1","key":"3088_CR102","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. The Pharmacogenomics Journal 5(1):6\u201313","journal-title":"The Pharmacogenomics Journal"},{"issue":"3","key":"3088_CR103","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","volume":"17","author":"CF Samer","year":"2013","unstructured":"Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Molecular Diagnosis & Therapy 17(3):165\u2013184","journal-title":"Molecular Diagnosis & Therapy"},{"issue":"3","key":"3088_CR104","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496\u2013526","journal-title":"Pharmacol Ther"},{"issue":"5","key":"3088_CR105","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ygeno.2010.11.004","volume":"97","author":"Y Xiong","year":"2011","unstructured":"Xiong Y, Wang M, Fang K, Xing Q, Feng G, Shen L, He L, Qin S (2011) A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics. 97(5):277\u2013281","journal-title":"Genomics."},{"issue":"8","key":"3088_CR106","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3109\/00498254.2015.1115914","volume":"46","author":"T Jin","year":"2016","unstructured":"Jin T, Xun X, Du S, Geng T, Wang H, Feng T et al (2016) Genetic polymorphisms analysis of drug-metabolizing enzyme CYP2C9 in the Uyghur population. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 46(8):709\u2013714","journal-title":"Xenobiotica; the Fate of Foreign Compounds in Biological Systems"},{"issue":"1","key":"3088_CR107","first-page":"3","volume":"16","author":"CN Sanchez-Dominguez","year":"2018","unstructured":"Sanchez-Dominguez CN, Gallardo-Blanco HL, Salinas-Santander MA, Ortiz-Lopez R (2018) Uridine 5\u2032-diphospho-glucronosyltrasferase: its role in pharmacogenomics and human disease. Experimental and Therapeutic Medicine 16(1):3\u201311","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"7","key":"3088_CR108","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm\u00f6ller J, Johne A et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97(7):3473\u20133478","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3088_CR109","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00210-006-0040-y","volume":"372","author":"J K\u00f6nig","year":"2006","unstructured":"K\u00f6nig J, Seithel A, Gradhand U, Fromm MF (2006) Pharmacogenomics of human OATP transporters. Naunyn Schmiedeberg\u2019s Arch Pharmacol 372(6):432\u2013443","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"2","key":"3088_CR110","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse C, Brockm\u00f6ller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60(2):284\u2013295","journal-title":"Am J Hum Genet"},{"key":"3088_CR111","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","volume":"41","author":"HG Xie","year":"2001","unstructured":"Xie HG, Kim RB, Wood AJ, Stein CM (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41:815\u2013850","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"3088_CR112","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1017\/S1461145798001187","volume":"1","author":"LD Bradford","year":"1998","unstructured":"Bradford LD, Kirlin WG (1998) Polymorphism of CYP2D6 in black populations: implications for psychopharmacology. Int J Neuropsychopharmacol 1(2):173\u2013185","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"3088_CR113","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1517\/14622416.3.2.229","volume":"3","author":"LD Bradford","year":"2002","unstructured":"Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 3(2):229\u2013243","journal-title":"Pharmacogenomics."},{"issue":"36","key":"3088_CR114","doi-asserted-by":"publisher","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","volume":"23","author":"MP Goetz","year":"2005","unstructured":"Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(36):9312\u20139318","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"33","key":"3088_CR115","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","volume":"25","author":"W Schroth","year":"2007","unstructured":"Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 25(33):5187\u20135193","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology."},{"issue":"13","key":"3088_CR116","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jama.2009.1420","volume":"302","author":"W Schroth","year":"2009","unstructured":"Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bol\u00e4nder J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Jama. 302(13):1429\u20131436","journal-title":"Jama."},{"issue":"11","key":"3088_CR117","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1517\/17425255.2014.964204","volume":"10","author":"A LLerena","year":"2014","unstructured":"LLerena A, Naranjo ME, Rodrigues-Soares F, Penas LEM, Fari\u00f1as H, Tarazona-Santos E (2014) Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol 10(11):1569\u20131583","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"3088_CR118","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/ijc.31291","volume":"143","author":"B Lan","year":"2018","unstructured":"Lan B, Ma F, Zhai X, Li Q, Chen S, Wang J, Fan Y, Luo Y, Cai R, Yuan P, Zhang P, Li Q, Xu B (2018) The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int J Cancer 143(1):184\u2013189","journal-title":"Int J Cancer"},{"issue":"8","key":"3088_CR119","first-page":"3585","volume":"8","author":"L Lei","year":"2016","unstructured":"Lei L, Wang X, Wu XD, Wang Z, Chen ZH, Zheng YB et al (2016) Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population. Am J Transl Res 8(8):3585\u20133592","journal-title":"Am J Transl Res"},{"issue":"8","key":"3088_CR120","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/annonc\/mdn155","volume":"19","author":"Y Xu","year":"2008","unstructured":"Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, He L, Li P, Xie Y (2008) Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Annals of Oncology: Official Journal of the European Society for Medical Oncology 19(8):1423\u20131429","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"25","key":"3088_CR121","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1200\/JCO.2007.11.4850","volume":"25","author":"HS Lim","year":"2007","unstructured":"Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 25(25):3837\u20133845","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology."},{"issue":"59","key":"3088_CR122","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.18632\/oncotarget.22220","volume":"8","author":"HI Woo","year":"2017","unstructured":"Woo HI, Lee SK, Kim J, Kim SW, Yu J, Bae SY, Lee JE, Nam SJ, Lee SY (2017) Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget. 8(59):100296\u2013100311","journal-title":"Oncotarget."},{"key":"3088_CR123","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fphar.2019.00530","volume":"10","author":"Z Khalaj","year":"2019","unstructured":"Khalaj Z, Baratieh Z, Nikpour P, Schwab M, Schaeffeler E, Mokarian F, Khanahmad H, Salehi R, M\u00fcrdter TE, Salehi M (2019) Clinical trial: CYP2D6 related dose escalation of Tamoxifen in breast Cancer patients with Iranian ethnic background resulted in increased concentrations of Tamoxifen and its metabolites. Front Pharmacol 10:530","journal-title":"Front Pharmacol"},{"key":"3088_CR124","first-page":"73","volume":"5","author":"N Areepium","year":"2013","unstructured":"Areepium N, Panomvana D, Rungwanonchai P, Sathaporn S, Voravud N (2013) Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients. Breast cancer (Dove Medical Press) 5:73\u201378","journal-title":"Breast cancer (Dove Medical Press)"},{"issue":"9","key":"3088_CR125","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.7314\/APJCP.2012.13.9.4549","volume":"13","author":"C Sukasem","year":"2012","unstructured":"Sukasem C, Sirachainan E, Chamnanphon M, Pechatanan K, Sirisinha T, Ativitavas T, Panvichian R, Ratanatharathorn V, Trachu N, Chantratita W (2012) Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pacific Journal of Cancer Prevention: APJCP 13(9):4549\u20134553","journal-title":"Asian Pacific Journal of Cancer Prevention: APJCP"},{"issue":"3\u20134","key":"3088_CR126","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000363304","volume":"94","author":"M G\u00fcnald\u0131","year":"2014","unstructured":"G\u00fcnald\u0131 M, Erkisi M, Af\u015far CU, Er\u00e7olak V, Paydas S, Kara IO et al (2014) Evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment. Pharmacology. 94(3\u20134):183\u2013189","journal-title":"Pharmacology."},{"issue":"5","key":"3088_CR127","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1365-2125.2011.03905.x","volume":"71","author":"JS Lim","year":"2011","unstructured":"Lim JS, Chen XA, Singh O, Yap YS, Ng RC, Wong NS et al (2011) Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 71(5):737\u2013750","journal-title":"Br J Clin Pharmacol"},{"key":"3088_CR128","first-page":"249","volume":"9","author":"W Charoenchokthavee","year":"2017","unstructured":"Charoenchokthavee W, Areepium N, Panomvana D, Sriuranpong V (2017) Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients. Breast Cancer (Dove Medical Press) 9:249\u2013256","journal-title":"Breast Cancer (Dove Medical Press)"},{"key":"3088_CR129","first-page":"37","volume":"6","author":"M Chamnanphon","year":"2013","unstructured":"Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C (2013) Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmacogenomics and Personalized Medicine 6:37\u201348","journal-title":"Pharmacogenomics and Personalized Medicine"},{"key":"3088_CR130","first-page":"149","volume":"5","author":"E Sirachainan","year":"2012","unstructured":"Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C (2012) CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmacogenomics and Personalized Medicine. 5:149\u2013153","journal-title":"Pharmacogenomics and Personalized Medicine."},{"issue":"5","key":"3088_CR131","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/j.1349-7006.2008.00780.x","volume":"99","author":"K Kiyotani","year":"2008","unstructured":"Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, Kubo M, Nakamura Y, Zembutsu H (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99(5):995\u2013999","journal-title":"Cancer Sci"},{"issue":"1","key":"3088_CR132","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1208\/s12248-011-9313-6","volume":"14","author":"LK Teh","year":"2012","unstructured":"Teh LK, Mohamed NI, Salleh MZ, Rohaizak M, Shahrun NS, Saladina JJ, Shia JKS, Roslan H, Sood S, Rajoo TS, Muniandy SP, Henry G, Ngow HA, Hla U KT, Din J (2012) The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J 14(1):52\u201359","journal-title":"AAPS J"},{"issue":"8","key":"3088_CR133","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1200\/JCO.2009.25.7246","volume":"28","author":"K Kiyotani","year":"2010","unstructured":"Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. Journal of clinical Oncology: Official Journal of the American Society of Clinical Oncology. 28(8):1287\u20131293","journal-title":"Journal of clinical Oncology: Official Journal of the American Society of Clinical Oncology."},{"issue":"8","key":"3088_CR134","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/1078-0432.CCR-16-1779","volume":"23","author":"H Zembutsu","year":"2017","unstructured":"Zembutsu H, Nakamura S, Akashi-Tanaka S, Kuwayama T, Watanabe C, Takamaru T, Takei H, Ishikawa T, Miyahara K, Matsumoto H, Hasegawa Y, Kutomi G, Shima H, Satomi F, Okazaki M, Zaha H, Onomura M, Matsukata A, Sagara Y, Baba S, Yamada A, Shimada K, Shimizu D, Tsugawa K, Shimo A, Tan EY, Hartman M, Chan CW, Lee SC, Nakamura Y (2017) Significant effect of polymorphisms in CYP2D6 on response to Tamoxifen therapy for breast cancer: a prospective multicenter study. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 23(8):2019\u20132026","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"3088_CR135","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10147-018-1346-8","volume":"24","author":"X Liu","year":"2019","unstructured":"Liu X, Huang X, Zhang S, Niu F, Ouyang Y, Shou Z, Liu J (2019) Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population. Int J Clin Oncol 24(2):179\u2013188","journal-title":"Int J Clin Oncol"},{"issue":"13","key":"3088_CR136","doi-asserted-by":"publisher","first-page":"20925","DOI":"10.18632\/oncotarget.14995","volume":"8","author":"SH Kuo","year":"2017","unstructured":"Kuo SH, Yang SY, You SL, Lien HC, Lin CH, Lin PH, Huang CS (2017) Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. Oncotarget. 8(13):20925\u201320938","journal-title":"Oncotarget."},{"key":"3088_CR137","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/PGPM.S44006","volume":"6","author":"I Sensorn","year":"2013","unstructured":"Sensorn I, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Sukasem C, Pinthong D (2013) Association of CYP3A4\/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmacogenomics and Personalized Medicine. 6:93\u201398","journal-title":"Pharmacogenomics and Personalized Medicine."},{"key":"3088_CR138","doi-asserted-by":"publisher","first-page":"563","DOI":"10.12659\/MSM.893473","volume":"21","author":"X Zhang","year":"2015","unstructured":"Zhang X, Pu Z, Ge J, Shen J, Yuan X, Xie H (2015) Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 21:563\u2013569","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research"},{"key":"3088_CR139","first-page":"2121","volume":"9","author":"I Sensorn","year":"2016","unstructured":"Sensorn I, Sukasem C, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Pinthong D, Wongwaisayawan S (2016) ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. OncoTargets and Therapy 9:2121\u20132129","journal-title":"OncoTargets and Therapy"},{"issue":"10","key":"3088_CR140","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s40262-016-0402-7","volume":"55","author":"N Sutiman","year":"2016","unstructured":"Sutiman N, Lim JSL, Muerdter TE, Singh O, Cheung YB, Ng RCH, Yap YS, Wong NS, Ang PCS, Dent R, Schroth W, Schwab M, Khor CC, Chowbay B (2016) Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on tamoxifen disposition in Asian breast cancer patients. Clin Pharmacokinet 55(10):1239\u20131250","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3088_CR141","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10549-011-1425-2","volume":"131","author":"IH Park","year":"2012","unstructured":"Park IH, Ro J, Park S, Lim HS, Lee KS, Kang HS, Jung SY, Lee S (2012) Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 131(2):455\u2013461","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3088_CR142","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/0284186X.2013.840739","volume":"53","author":"A Markkula","year":"2014","unstructured":"Markkula A, Hjertberg M, Rose C, Ingvar C, Jernstr\u00f6m H (2014) No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients. Acta oncologica (Stockholm, Sweden) 53(2):195\u2013200","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"issue":"21","key":"3088_CR143","doi-asserted-by":"publisher","first-page":"6944","DOI":"10.1158\/1078-0432.CCR-11-0860","volume":"17","author":"MP Goetz","year":"2011","unstructured":"Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M, Batzler A, Costantino JP, Vogel VG, Paik S, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM, Ingle JN, Ames MM (2011) Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 17(21):6944\u20136951","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research."},{"issue":"9","key":"3088_CR144","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"M Baum","year":"2003","unstructured":"Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists\u2019 Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer. 98(9):1802\u20131810","journal-title":"Cancer."},{"issue":"2","key":"3088_CR145","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/JCO.2001.19.2.322","volume":"19","author":"S Demissie","year":"2001","unstructured":"Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 19(2):322\u2013328","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology."},{"issue":"9247","key":"3088_CR146","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","volume":"356","author":"CL Loprinzi","year":"2000","unstructured":"Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL et al (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet (London, England) 356(9247):2059\u20132063","journal-title":"Lancet (London, England)"},{"issue":"6","key":"3088_CR147","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2217\/pgs.13.47","volume":"14","author":"S Margolin","year":"2013","unstructured":"Margolin S, Lindh JD, Thor\u00e9n L, Xie H, Koukel L, Dahl ML, Eliasson E (2013) CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics. 14(6):613\u2013622","journal-title":"Pharmacogenomics."},{"issue":"Suppl 3","key":"3088_CR148","first-page":"S1","volume":"3","author":"VC Jordan","year":"2011","unstructured":"Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H, The St. Gallen Prize Lecture et al (2011) Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast (Edinburgh, Scotland). 2011;20. Suppl 3(Suppl 3):S1\u2013S11","journal-title":"Suppl"},{"issue":"1","key":"3088_CR149","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/tpj.2014.34","volume":"15","author":"P Saladores","year":"2015","unstructured":"Saladores P, M\u00fcrdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JSL, Yap YS, Ng RCH, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H (2015) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. The Pharmacogenomics Journal. 15(1):84\u201394","journal-title":"The Pharmacogenomics Journal."},{"issue":"6","key":"3088_CR150","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Th\u00fcrlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G, Breast International Group (BIG) 1-98 Collaborative Group (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104(6):441\u2013451","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"3088_CR151","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104(6):452\u2013460","journal-title":"J Natl Cancer Inst"},{"key":"3088_CR152","doi-asserted-by":"crossref","unstructured":"Benetkiewicz M, Piotrowski A, D\u00edaz De St\u00e5hl T, Jankowski M, Bala D, Hoffman J, et al. Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int J Oncol 2006;29(4):935\u2013945","DOI":"10.3892\/ijo.29.4.935"},{"issue":"30","key":"3088_CR153","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.2017.73.3246","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN (2017) First-in-human phase I study of the Tamoxifen metabolite Z-Endoxifen in women with endocrine-refractory metastatic breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 35(30):3391\u20133400","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology."},{"issue":"2","key":"3088_CR154","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/tpj.2017.36","volume":"18","author":"GS Hwang","year":"2018","unstructured":"Hwang GS, Bhat R, Crutchley RD, Trivedi MV (2018) Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. The Pharmacogenomics Journal. 18(2):201\u2013208","journal-title":"The Pharmacogenomics Journal."},{"issue":"4","key":"3088_CR155","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/0091270009359182","volume":"50","author":"S Borges","year":"2010","unstructured":"Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S et al (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50(4):450\u2013458","journal-title":"J Clin Pharmacol"},{"key":"3088_CR156","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3389\/fphar.2017.00582","volume":"8","author":"W Schroth","year":"2017","unstructured":"Schroth W, Winter S, M\u00fcrdter T, Schaeffeler E, Eccles D, Eccles B, Chowbay B, Khor CC, Tfayli A, Zgheib NK, Eichelbaum M, Schwab M, Brauch H (2017) Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front Pharmacol 8:582","journal-title":"Front Pharmacol"},{"issue":"3","key":"3088_CR157","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ctrv.2015.01.002","volume":"41","author":"L Binkhorst","year":"2015","unstructured":"Binkhorst L, Mathijssen RH, Jager A, van Gelder T (2015) Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev 41(3):289\u2013299","journal-title":"Cancer Treat Rev"},{"key":"3088_CR158","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1471-2180-9-126","volume":"9","author":"CY Tay","year":"2009","unstructured":"Tay CY, Mitchell H, Dong Q, Goh KL, Dawes IW, Lan R (2009) Population structure of helicobacter pylori among ethnic groups in Malaysia: recent acquisition of the bacterium by the Malay population. BMC Microbiol 9:126","journal-title":"BMC Microbiol"},{"issue":"4","key":"3088_CR159","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.tips.2005.02.008","volume":"26","author":"G Suarez-Kurtz","year":"2005","unstructured":"Suarez-Kurtz G (2005) Pharmacogenomics in admixed populations. Trends Pharmacol Sci 26(4):196\u2013201","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"3088_CR160","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"J Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17(2):93\u2013101","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"3088_CR161","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/pgs-2019-0073","volume":"21","author":"X Wei","year":"2020","unstructured":"Wei X, Cai J, Zhuang J, Zheng B, Sui Y, Zhang G, Lin Y, Sun H (2020) CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer. Pharmacogenomics. 21(1):43\u201353","journal-title":"Pharmacogenomics."}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03088-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03088-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03088-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T03:41:51Z","timestamp":1666755711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03088-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":161,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3088"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03088-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"17 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}